Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cell Therapy in Mental Retardation
NCT02245724Phase 1Withdrawn
- Sponsor
- NeuroGen Brain & Spine Institute
- Start
- Sep 2011
- Primary completion
- Mar 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in intellectual disability (ID), sponsored by NeuroGen Brain & Spine Institute. Primary endpoint: Change in common clinical symptoms of mental retardation at 1 year. Planned start Sep 2011; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
intellectual disability (ID)
Beyond the preview
Go deeper on NCT02245724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245724.